Synthetic Antibody Rallies Immune Cells Against Ovarian Cancer
NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody. READ FULL ARTICLE
NIH Intramural Research Program (IRP) highlights Precision Biologics NEO-201 monoclonal antibody. READ FULL ARTICLE
Precision Biologics in conjunction with our research collaborators at the National Cancer Institute (NCI) have...
Precision Biologics along with our collaborators at the National Cancer Institute present research data using...
Precision Biologics announces that the results of the Phase II Clinical Trial using its lead...
Dr Massimo Fantini, Senior Scientist is Presenting the following Talk entitled: "Mechanisms of action of...
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients...
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas VIEW...
Rockville, MD, April 2, 2017 - Precision-Biologics Inc.